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the impact of neutron dose
outside of the treatment
fields. Measuring neutron
dose is challenging because
of the need to accurately ac-
count for the energy spec-
trum. This comprehensive
measurement study ad-
dresses this issue specifically
for CSI on the single-room
Mevion S250 proton system.Reprint requests to: Rebecca M. Howell, PhD
Physics, The University of Texas M. D. Anderso
TX 77030. Tel: (713) 745-8999; E-mail: rhowe
Conflict of interest: none.
Supplementary material for this article
redjournal.org.
AcknowledgmentsdThe authors thank Br
Caesar Chiaradonna, and Alan Anganes, the
Int J Radiation Oncol Biol Phys, Vol. 95, No. 1
0360-3016/ 2016 The Authors. Published by
licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.ijrobp.2015.12.356Purpose: To measure, in the setting of typical passively scattered proton craniospinal
irradiation (CSI) treatment, the secondary neutron spectra, and use these spectra to
calculate dose equivalents for both internal and external neutrons delivered via a
Mevion single-room compact proton system.
Methods and Materials: Secondary neutron spectra were measured using extended-
range Bonner spheres for whole brain, upper spine, and lower spine proton fields.
The detector used can discriminate neutrons over the entire range of the energy spec-
trum encountered in proton therapy. To separately assess internally and externally
generated neutrons, each of the fields was delivered with and without a phantom.
Average neutron energy, total neutron fluence, and ambient dose equivalent [H*
(10)] were calculated for each spectrum. Neutron dose equivalents as a function of
depth were estimated by applying published neutron depthedose data to in-air H*
(10) values.
Results: For CSI fields, neutron spectra were similar, with a high-energy direct
neutron peak, an evaporation peak, a thermal peak, and an intermediate continuum be-
tween the evaporation and thermal peaks. Neutrons in the evaporation peak made the
largest contribution to dose equivalent. Internal neutrons had a very low to negligible, Department of Radiation
n Cancer Center, Houston,
ll@mdanderson.org
can be found at www.
ad Hawkins, Jeff Heine,
Mevion engineers who
participated in more than 40 hours of measurements, particularly for
their expertise in operating the machine at very low dose rates, thereby
making possible the use of an active detection technique. The authors also
thank Ms. Kathryn Hale from The University of Texas M. D. Anderson
Cancer Center Department of Scientific Publications for assistance in
editing the manuscript; and Dr Phillip J. Taddei for his feedback on a draft
of the manuscript.
, pp. 249e257, 2016
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Howell et al. International Journal of Radiation Oncology  Biology  Physics250The resulting dose equivalent
was found to be in line with
other proton systems.contribution to dose equivalent compared with external neutrons, largely attributed to
the measurement location being far outside the primary proton beam. Average energies
ranged from 8.6 to 14.5 MeV, whereas fluences ranged from 6.91  106 to 1.04  107
n/cm2/Gy, and H* (10) ranged from 2.27 to 3.92 mSv/Gy.
Conclusions: For CSI treatments delivered with a Mevion single-gantry proton ther-
apy system, we found measured neutron dose was consistent with dose equivalents re-
ported for CSI with other proton beamlines.  2016 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Craniospinal irradiation (CSI), which involves irradiating
the entire craniospinal axis, is part of the standard of care in
the treatment of several pediatric brain tumors, including
medulloblastoma, the second most common solid tumor in
children (1-3). Proton radiation therapy substantially re-
duces radiation dose to organs situated outside the cranio-
spinal axis (4-9) compared with photon therapy because of
its lower entrance dose and essentially no exit dose. Despite
these proven advantages, secondary neutrons, an unavoid-
able consequence of any proton therapy technique, remain
a concern. This concern is somewhat heightened for
passively scattered versus magnetically scanned techniques
because of the additional high atomic number materials in
the beamline for the former (10, 11). Dose from secondary
neutrons is of particular concern in proton CSI because this
treatment is almost universally utilized for children and
adolescents, who often survive many decades after diag-
nosis (12-14) and are at significant risk of radiation-related
late effects, including second malignancies in the years
following their treatment (15, 16).
Compared with therapeutic protons, secondary neutron
exposure is low. Nonetheless, it is important to under-
stand its contribution to the overall patient dose. Doses
from neutrons generated external to the patient (external
neutrons) are highly dependent on the proton beam
incident on the patient, which depends on the design of
the proton therapy machine itself and treatment-specific
devices within the beamline (17). Doses from neutrons
generated within the patient (internal neutrons) increase
with beam range and treatment volume irradiated (ie,
field size) (18, 19).
Doses from both internal and external neutrons calcu-
lated by Monte Carlo simulations of passively scattered
proton CSI have been reported in the literature (19-23), but
data based on spectra measurements are lacking. This gap
in the literature is a direct consequence of the limitations
of various neutron detectors, including limited energy
discrimination, limited response to neutrons having energies
greater than 20 MeV, and pulse pile-up for active detectors
(Kry et al, unpublished). Extended-range Bonner spheres
with appropriate energy sensitivity have been used in 2
other studies (24, 25) to measure secondary neutron spectrafrom proton therapy, but neither study considered CSI
fields, which tend to have apertures with substantial
exposed brass. Those studies were carried out specifically
for the Hitachi (Hitachi Probeat; Hitachi America Limited,
Tarrytown, NJ) and IBA (Ion Beam Applications SA,
Louvain-la-Neuve, Belgium) beamlines. Furthermore, the
extensive Monte Carlo data for neutron doses from proton
CSI that have been reported are mainly for Hitachi proton
beam lines, with a lack of neutron doses reported for other
systems now in use. The Mevion (Mevion s250; Mevion
Medical Systems, Littleton, MA) single-room compact
proton systems are particularly noteworthy because world-
wide 4 units are currently clinically operational, 2 are under
installation (accelerator in place), and 2 more are under
construction (at the time of this submission) (26).
The objectives of this study were, for a passively scat-
tered proton CSI treatment delivered via a single-room
compact proton system, (1) to measure the secondary
neutron spectra with a detector that can discriminate neu-
trons over the entire range of the energy spectra encoun-
tered in proton therapy; (2) to use the measured neutron
spectra to calculate dose equivalents; and (3) to report these
data for both internal and external neutrons specifically.Methods and Materials
Measurements
Measurements were made in a single-room passively
scattered proton therapy treatment room, which houses a
synchrocyclotron accelerator system (Mevion 250, Mevion
Medical Systems). This system can deliver passively scat-
tered proton beams up to 250 MeV utilizing a 9.6-Tesla
superconducting magnet, which handles up to 2000 amps of
current. The passive scattering system includes an initial
scatterer, range modulator wheels, secondary scatterers,
and various absorbers to give range designation and flat
profiles. The range and modulation are defined as the dis-
tance in centimeters from the surface to the distal 90% dose
and from the proximal 95% dose to the distal 90% dose,
respectively. The field size is defined with either a large
(25-cm diameter) or small (14-cm diameter) applicator.
Table 1 Summary of the beam delivery parameters for each craniospinal irradiation field for which neutrons were measured
Field type Beam incident on
Gantry
angle ()
Couch
angle ()
Aperture
size
Blocked by
aperture (%) Range (cm) Modulation (cm)
Whole brain Air, water, anthropomorphic 90 270 Large 51.5 17 16
Upper spine Air, water 0 270 Large 57.5 10 8
Lower spine Air, water, plastic water 0 270 Large 61.2 10 8
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50 cm (along the patient axis) from isocenter to ensure that
our active detector was not affected by pulse pile-up. The
beam delivery parameters are summarized in Table 1, and
the treatment fields comprised whole brain, upper spine,
and lower spine based on an actual patient’s treatment.
Each treatment field was delivered using the large aperture
(nominal open diameter of 25 cm at 2 m physical source-
to-axis distance), into which treatment fieldespecific ap-
ertures were added; percentage of blocking is listed in
Table 1. To separately assess internally and externally
generated neutrons, each of the 3 treatments was repeated
with and without a water phantom (35  35  35 cm3)
directly under the beam at isocenter. Additionally, the
whole-brain treatment was delivered to an anthropomor-
phic phantom (head to clavicle) at isocenter to evaluate
whether internal neutron production differed for water and
for a phantom having a more complex elemental compo-
sition. Finally, to assess whether there was any difference
in internal neutrons generated in water and those gener-
ated in plastic water, the lower spine field was also
delivered with plastic water at isocenter. The experimental
setups for the brain and upper spine irradiations are shown
in Figure 1 in the Supplementary Material (available online
at www.redjournal.org).
For each of the clinical field types, we performed proton
dose measurements in a water phantom to determine the
exact therapeutic proton dose delivered in grays (Gy) per
monitor unit (MU). These data were then used to normalize
the measured neutron data per proton Gy. Because mea-
surements were performed with dose rates that are below
those used clinically, dose rate linearity was tested from
clinical rates (120 to 200 MU/min) down to those used in
this study (15 to 20 MU/min).
Neutron detection equipment
We used an extended-range Bonner sphere spectrometer,
the Bonner sphere extension (BSE) measurement system, to
perform measurements. The advantage of this detection
system is that, unlike standard Bonner spheres, it is sensi-
tive to neutrons over the entire energy range encountered in
proton therapy (thermal to 250 MeV) and has sufficient
energy discrimination for spectral measurements. We
briefly summarize the detection system here; a more thor-
ough description is available in the literature (25, 27, 28).
The BSE is a modular multisphere system with a total of 18
sphere combinations that includes 6 standard polyethyleneBonner spheres (ranging from 5.1 cm to 30.5 cm diameters)
and 12 extended-sphere combinations. The extended
spheres include various combinations that have either a 7.6-
cm or a 12.7-cm Bonner sphere surrounded by a copper,
tungsten, or lead shell that can be further encased in an
outer polyethylene sphere. In the present study we used an
active 6LiI(Eu) scintillator (Ludlum Measurements,
Sweetwater, TX), necessitating accelerator engineers to
tune the beam to very low proton dose rates to avoid pulse
pile-up and erroneous results. Using the active detector, we
were able to measure sufficient neutron counts to achieve
uncertainties of <1% with very short beam-on times, on
average 1 to 1.5 minutes. In total we carried out 8 sets of
measurements for various CSI fields (described in the
following section), each set including 18 separate mea-
surements with the detector centered inside each of the 18
detector-sphere combinations. These data required mathe-
matical deconvolution to determine the neutron spectra.Spectrum unfolding
Data for each of the 8 sets ofmeasurements were unfolded by
using the MAXimum Entropy Deconvoloution (MAXED
MXD_FC33) algorithm, of the UMG software package,
version 3.3.44 (29, 30). Spectrum unfolding required
measured data, an a priori (ie, starting) spectrum, and
response functions for each detector sphere combination. A
starting spectrum was determined by using a previously
described Bayesian statistical method (25, 29). A separate
response function was previously calculated (27, 28) for the
BSE detector-sphere combinations using the Monte Carlo
N-Particle Code eXtended (MCNPX) code (31).Calculated neutron parameters
The average neutron energy and total neutron fluence were
calculated for each measured neutron spectrum over the
entire energy range from thermal up to the maximum
neutron energy. Because neutrons with energy less than
10 keV have a negligible contribution to the dose equiva-
lent, fluence and average energy were also computed
without these low-energy neutrons. Ambient dose equiva-
lents [H* (10)] were calculated by applying International
Commission on Radiation Protection and Measurements
publication 74 conversion coefficients (32, 33) to the flu-
ence spectra.
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Fig. 1. Comparison of neutron fluence spectra measured at a distance of 50 cm from isocenter for passively scattered
proton craniospinal irradiation fields delivered to (a) whole brain, upper spine, and lower spine fields incident on a
35  35  35-cm3 water phantom at the isocenter, (b) whole-brain fields, (c) upper spine fields, and (d) lower spine fields.
Data in (b), (c), and (d) were measured with no phantom and water phantom at isocenter. For (b) and (d), additional
measurements were performed with anthropomorphic and plastic water phantoms at isocenter, respectively.
Howell et al. International Journal of Radiation Oncology  Biology  Physics252In a clinical CSI treatment, many organs of interest are
much closer to the proton fields than our measurement
location of 50 cm from the field isocenter. Thus, H* (10)
values at 30 cm from isocenter were approximated by
applying an analytical function relating dose and distance
from the isocenter to the measured H* (10) data at 50 cm.
The analytical function was derived from a series of spectra
measurements that were performed using the small aperture
with a solid brass insert added to achieve a “closed field.”
This beamline configuration made it possible to place the
detector closer to the isocenter without any pulse pile-up
because the neutron fluence for the small aperture field was
substantially (approximately 2-fold) lower than for CSI
fields that required the large aperture. With this configu-
ration, we performed in-air spectra measurements with the
BSE measurement system at isocenter and at 40 cm and
100 cm from the isocenter. The H* (10) at each locationwere computed and plotted as function of distance from
isocenter (x). The data were fit to a second order poly-
nomial model; dose Z 0.0003x20.0598x þ 3.85
(R2Z0.98). Using these data, we calculated a ratio of 1.44
for neutron doses at 30 cm compared with 50 cm from
isocenter.
Neutron dose falls off rapidly with depth in a patient
(Kry et al, unpublished). Thus, H* (10), an in-air quantity,
will overestimate patient dose. As such, to provide real-
istic estimates of dose in a patient, we estimated neutron
dose equivalent as a function of depth by applying pub-
lished neutron depthedose data (34) to the in-air H* (10)
values. This methodology has been previously reported in
the literature (35-37) and is also recommended in an
upcoming Task Group Report from the American Asso-
ciation of Physicists in Medicine (Kry et al, unpublished).
Depthedose curves were selected on the basis of the
Volume 95  Number 1  2016 Neutrons from single-room proton CSI 253average neutron energies at 30 cm (13.5 MeV) and 50 cm
(11.7 MeV) from isocenter. Finally, we multiplied neutron
dose equivalent per therapeutic Gy by 23.4 to estimate the
values for a full course of CSI for low- to mid-grade
medulloblastoma. However, because our estimated dose
equivalents at depth were not specific to any organs, we
could not apply organ weighting factors, and therefore it
is not possible to calculate a whole-body effective dose.Results
The measured neutron spectral fluence for each field type
and measurement setup are shown in Figure 1. The dif-
ferences in treatment type are highlighted in Figure 1a, and
the effects of having no phantom versus water, plastic
water, or anthropomorphic phantoms are illustrated in1.2E+00
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Fig. 2. Comparison of neutron ambient dose equivalent H* (10
passively scattered proton craniospinal irradiation fields deliver
incident on a 35  35  35 cm3 water phantom at the isocenter,
spine fields. Data in (b), (c), and (d) were measured with no p
additional measurements were performed with anthropomorphicFigure 1bed. The corresponding ambient dose equivalent
spectra are shown in Figure 2. Both figures are plotted on a
log-linear scale, and fluence and dose equivalent are given
per unit lethargy, so that the relative fluence and dose
equivalent and contributions from each energy bin are
proportional to the area under the histogram.
The average energies, total fluence, and ambient dose
equivalents per proton Gy are listed in Table 2 over the
energy ranges of thermal to 210 MeV and 10 keV to
210 MeV. When all neutrons are considered, average en-
ergies and fluences range from 5.3 MeV to 10.0 MeV and
from 1.12  107 to 1.52  107 n/cm2/Gy, respectively.
When only neutrons greater than 10 keV are considered,
average energies are higher, ranging between 8.6 to
14.5 MeV, whereas fluences are lower, ranging from
6.91  106 to 1.04  107 n/cm2/Gy. The exclusion of
neutrons with energy less than 10 keV made almost no1.0E-09 1.0E-07 1.0E-05 1.0E-03 1.0E-01 1.0E+01 1.0E+03
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) spectra measured at a distance of 50 cm from isocenter for
ed to (a) whole brain, upper spine, and lower spine fields
(b) whole-brain fields, (c) upper spine fields, and (d) lower
hantom and water phantom at isocenter. For (b) and (d),
and plastic water phantoms at isocenter, respectively.
Table 2 Derived neutron parameters per proton Gy delivered to isocenter for whole brain, upper spine, and lower spine craniospinal
irradiation fields for measurements at 50 cm from isocenter
Field type Beam incident on
Average energy (MeV)
Fluence per proton Gy
(n/cm2/Gy)
H* (10) per proton
Gy (mSv/Gy)
Thermal to
210 MeV
10 keV to
210 MeV
Thermal to
210 MeV
10 keV to
210 MeV
Thermal to
210 MeV
10 keV to
210 MeV
Whole brain No phantom (air) 10.0 14.5 1.52Eþ07 1.04Eþ07 3.95 3.92
Water phantom 9.9 13.1 1.52Eþ07 1.04Eþ07 3.94 3.90
Anthropomorphic phantom 10.0 14.5 1.52Eþ07 1.04Eþ07 3.95 3.92
Upper spine No phantom (air) 5.3 8.6 1.12Eþ07 6.91Eþ06 2.30 2.27
Water phantom 7.5 12.6 1.34Eþ07 7.99Eþ06 2.79 2.75
Lower spine No phantom (air) 5.4 8.6 1.28Eþ07 7.92Eþ06 2.63 2.60
Water phantom 5.9 9.4 1.29Eþ07 8.06Eþ06 2.71 2.68
Plastic water phantom 5.4 8.6 1.28Eþ07 7.92Eþ06 2.63 2.59
Data are indicated separately for in-air and with various different phantoms positioned at isocenter.
Howell et al. International Journal of Radiation Oncology  Biology  Physics254difference in the calculated ambient dose equivalent values,
which ranged from 2.27 to 3.95 mSv/Gy. These data are
separately listed in Table 2 for all 8 measurement scenarios
performed at 50 cm from the isocenter.
The estimated dose equivalents at depth in water are
listed in Table 3 for 30 cm and 50 cm from isocenter. The
data in Table 3 are for a 23.4-Gy prescribed proton dose.
Dose at depth is not shown for the 100-cm location because
this distance is beyond locations that would be of interest in
a patient.Discussion
We observed that internal neutrons made a very low to
negligible contribution to neutron dose equivalent, largely
attributed to the measurement location being perpendicular
to the primary proton beam. The energy distributions for
each of the fluence spectra (Fig. 1) were similar, with a
high-energy direct neutron peak, an evaporation peak, aTable 3 Neutron dose equivalents (mSv) for a 23.4-Gy course of
spine fields at 50 cm and 30 cm from isocenter as a function of dept
Depth (cm)
Dose equivalent (mSv) for
50 cm from isocenter
Whole brain Upper spine Lower sp
0.1 92.2 65.3 63.4
1 92.0 65.1 63.3
2 91.7 65.0 63.1
3 87.9 62.2 60.4
5 83.3 59.0 57.3
6 79.7 56.5 54.8
8 74.1 52.5 51.0
10 66.1 46.8 45.4
12 58.8 41.7 40.5
14 54.0 38.2 37.2
16 45.4 32.1 31.2
18 39.0 27.6 26.8
19.9 31.9 22.6 21.9thermal peak, and an intermediate continuum between the
evaporation and thermal peaks. Comparing Figures 1 and 2,
it is clear that neutrons in the evaporation peak made the
largest contribution to the dose equivalent. This is because
of both their relative abundance and their high-quality
conversion coefficients, the highest over this energy range
(32, 33). Neutron fluence and ambient dose equivalent were
approximately 1.6 times higher for the brain field than for
the spine fields (Figs. 1 and 2). This is attributed to the
higher range and modulation for the brain field than for the
spine fields (Table 2). For the whole brain and upper spine
fields, there was a nearly negligible difference in the flu-
ence for the different phantom scenarios (Figs. 1b, d and
2b, d); differences between no phantom at isocenter and
either a water or anthropomorphic phantom were <2%.
This indicates that at 50 cm from isocenter for these fields,
there was essentially no contribution from internal neu-
trons. At this large distance, neutrons created within the
patient volume irradiated by the fields would have been
attenuated by the intermediating tissue. A limitation of ourcraniospinal irradiation for whole-brain, upper spine, and lower
h in water
proton dose 23.4 Gy to beam isocenters
30 cm from isocenter
ine Whole brain Upper spine Lower spine
133.2 94.3 91.6
133.1 94.2 91.5
132.5 93.8 91.2
127.1 90.0 87.4
121.6 86.1 83.7
116.8 82.7 80.3
110.1 78.0 75.7
98.9 70.0 68.0
88.3 62.6 60.8
82.8 58.7 57.0
70.4 49.9 48.4
59.7 42.3 41.1
50.0 35.4 34.4
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dicular to the beam axis and not at varying angles to the
axis of the beam.
These results are consistent with data from prostate
fields reported for the Hitachi beam line by Fontenot et al
(18) indicating that neutron dose to organs beyond 50 cm
from proton beam isocenter was entirely due to external
neutrons. For the upper spine, some minor differences were
observed between the different phantom scenarios. Spe-
cifically, the total fluence was approximately 16% higher
when measurements were made with water phantom at
isocenter compared with measurements with no phantom at
isocenter. This difference in fluence translated to a differ-
ence of 20% in the ambient dose equivalent. This suggests
that, beyond 50 cm from the upper spine field, although
external neutrons were the dominant component of the
neutron dose, there was also some small contribution from
internal neutrons. We speculate that this was observed only
for this field and not the others because the upper spine field
(defined by the aperture opening) was longer than the lower
spine field, and thus the distance from the edge of this field
was closer to the measurement location. These findings are
not inconsistent with the literature. Fontenot et al (18) re-
ported that approximately 15% of the neutron dose was
attributed to internal neutrons at 30 cm from isocenter.
Although the distance in that study was closer than that
used in our study, that study considered only small prostate
fields, whereas we considered a large spine field.
Most of the Monte Carlo literature (21, 38) reports
organ dose equivalents or total effective dose equivalents
for the entire treatment, meaning the sum from all CSI
fields. In our study it was not possible to sum the dose
equivalents from the 3 fields, because although all of our
measurements were at 50 cm from isocenter, this point is
at a different location in the body for each field. Studies by
Newhauser et al (22) and Taddei et al (39) reported
neutron dose equivalents for individual fields in a CSI
treatment for the Hitachi beam line. However, those dose
equivalents were reported for various organs and structures
rather than at specified distances from isocenter, as in our
work. To compare our results with data from those 2
studies, we had to determine which of the organs from the
previous studies were at distances out-of-field comparable
to those for the data reported here. We were able to reviewTable 4 Comparison of dose equivalents per proton Gy to isocente
Study
Range (low and high values) of neutron do
Whole brain
Low value High value Low va
Taddei et al 0.9 4.5 1.0
This study 1.4 5.7 1.0
Here, we specifically report the range of dose equivalents from Taddei et a
respective beam isocenters. Those values were compared with the ranges of d
normalized per proton Gy in Table 4).the CT scan of the patient that was used in the study by
Taddei et al (39), allowing us to select organs whose po-
sitions were between 30 cm and 50 cm from the isocenter
of each field and to compare data from our study and their
study (Table 4).
Overall, our data are in reasonable agreement with those
of Taddei et al (39), with some differences; generally, the
dose equivalents in our study were somewhat higher. The
differences can in part be attributed to our reporting point
doses, whereas Taddei et al reported mean dose to organs
that spanned a range of depths. The differences in dose
equivalents between the 2 studies can also be attributed to
numerous other factors, including comparison of point
doses to dose averages calculated over the entire organ and
our application of a depthedose correction rather than the
more detailed particle tracking used by Taddei et al (39).
However, it should not be overlooked that there are dif-
ferences between the Hitachi and Mevion beamline designs
that directly affect the neutron production and neutron
doses for proton CSI from these 2 studies. Given all of
these factors, the dose equivalents reported in this study are
in good agreement with those of Taddei et al (39). As
previously mentioned, we cannot compare our data with
most of what is in the literature, where neutron doses for
CSI were not reported on an individual field basis or were
reported as effective doses to the entire body, or position of
the organ was not specified (relative to isocenter). However,
our data agree well with those of Taddei et al (39), which
were in reasonable agreement with the data from these
other studies (21, 22, 38).
We can also compare our data with out-of-field stray
dose (due to scatter and leakage radiation) from photon
CSI. Using the analytical model reported by Taddei et al
(40) for out-of-field stray dose from 6-MV photon CSI, we
estimated that at 50 cm from the isocenter, photon CSI
would result in 1.10  10-03 mSv/Gy and 5.00  10-
02 mSv/Gy for Varian 2100 and Siemens Artise linacs,
respectively. These photon doses are orders of magnitude
lower than the secondary neutron doses for the various CSI
proton fields reported here, 2.27 to 3.95 mSv/Gy at 50 cm
from the isocenter (Table 2). However, this type of com-
parison can be misleading because in actuality it has been
shown in the literature (21) that dose to nontarget organs is
far greater for photon CSI than for proton CSI, and inr from Taddei et al (39) and this study
se equivalents per proton Gy delivered to isocenter for CSI
fields (mSv/Gy)
Upper spine Lower spine
lue High value Low value High value
2.7 0.9 2.4
4.0 0.9 3.9
l (39) for organs whose locations were between 30 and 50 cm from the
oses listed in Table 3 for each field (note that data from Table 3 were
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ference is driven by the high exit dose from photon therapy;
the total photon organ dose is the sum of the exit dose and
the out-of-field stray dose, whereas for protons, there is
almost no exit dose and the organ dose is almost entirely
due to neutrons.
In this study we report neutron doses but have not spe-
cifically addressed the risk of second cancers in children
and adolescents who receive passively scattered proton
therapy with the Mevion single-room, passively scattered
proton system. Because these were point measurements and
not organ-specific doses, it is difficult to calculate risk of
second cancers to specific organs. However, because the
neutron doses reported here are consistent and in relatively
good agreement with organ doses from detailed Monte
Carlo studies that were used to predict second cancer risk
(21, 22, 38, 39), it is reasonable to hypothesize that the risk
of second cancers from proton CSI delivered on the Mevion
single-room, passively scattered proton system is similar to
that from other passively scattered proton systems (ie, the
Hitachi beam line). Nonetheless, efforts should be made to
further reduce secondary neutron dose in proton therapy. To
reduce the neutron dose, brain fields can be strategically
designed to introduce as little brass as possible. The advent
of beam scanning will also reduce neutron exposure as the
brass component, along with other field-shaping apparatus,
are removed.Conclusion
In this study we measured neutron spectra and character-
ized neutron dose equivalents for a clinical treatment for a
single gantry proton system, whose use and planned in-
stallations in the United States have recently increased.
Importantly, we considered CSI, commonly used proton
therapy for pediatric cancer, and found that the neutron
dose from this gantry system is, overall, consistent with
dose equivalents reported for CSI carried out with other
proton therapy beamlines.References
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